Márquez-González H, Ramírez-García MÁ, Villa-Romero AR

Language: Spanish
References: 24
Page: 205-210
PDF size: 241.15 Kb.

ABSTRACT

Huntington disease is a neurodegenerative disorder caused by expanded trinucleotides which encode polyglutamine tracts. The disease is inherited as an autosomal dominant trait with onset in adult life, normally between 37 to 55 years. Once the symptoms have started, life expectancy will be 15 years. The diagnosis is clinical and molecular after the establishment of the symptomatology. It is characterized by involuntary movements, psychiatric illness and cognitive impairment. There are two ways to approach the antenatal diagnosis in couples with familial background: prenatal and preimplantation. The current posture related to antenatal diagnosis is only for couples that desire termination of the pregnancy. This essay discusses this situation through medical principlism, and arrives to the following conclusions: regarding the principles of autonomy and integrity of the human being, the carrier of the disease is not respected. It does not seem fair to perform a test to determine the behavior of ending a life during pregnancy, while there are other diseases with similar prognosis that do not have the same diagnostic possibilities. This violates the principles of beneficence and non-maleficence, promoting death. We suggest that medical participation must promote the best conditions to confirm the diagnosis, and prepare both family and patient concerning the emotional, physical and nutritional aspects for the moment of the onset of the symptomatology.

REFERENCES

1. Roos R. Huntington disease: a clinical review. Orphanet J Rare Dis. 2010; 5: 40-8.

2. Quarell OWJ, Brewer HM, Squireti F, Barker RA, Nance MA, Landwhemeyer B. Juvenile Huntington disease. Oxford: Oxford University Press; 2009.

3. Grosse SD, Kalman L, Khoury MJ. Evaluation of the validity and utility of genetic testing for rare diseases. Adv Exp Med Biol. 2010; 686: 115-31.

4. Ross R, Vegter-van der Vlis M, Hermans J, Elshove H, Mole A, van de Kamp J et al. Age at onset in Huntington disease: effect of line of inheritance and patients, sex. J Med Gent. 1991; 28: 515-9.

5. Paulsen J, Ferneyhough K, Nehl C, Stierman L, The Huntington study group. Critical periods of suicide risk in Huntington’s disease. Am J Psych. 2005; 162: 725-31.

6. James R. Debate sobre el utilitarismo. En: James R. Introducción a la filosofía moral. México: McGraw Hill; 1990: p. 167-80.

7. Bergman J. The dark side of Charles Darwin: a critical analysis of an icon of science. Green Forest, Ark: Master Books; 2011.

8. Cruz-Coke MR. Normas bioéticas de UNESCO para evitar prácticas eugenésicas en investigaciones biomédicas. Rev Med Chile. 2000; 128: 679-82.

9. Fleishman AR, Chervenack FA, McCullogh LB. The physicians moral obligation to the pregnant woman, the fetus, and the child. Semin Perinatol. 1998; 22: 184-8.

10. Freedom RM, Yoo SJ. Tetralogy of Fallot with absent pulmonary valve. In: Freedom RM, Yoo SJ, Mikailian H, eds. The natural and modified history of congenial heart disease. Nueva York: Wiley-Blackwell Publishing; 2004: p. 212-16.

11. Lau TK, Chan MK, Lo PS, Chan HY, Chan WS, Koo TY et al. Clinical utility of noninvasive fetal trisomy (NIFTY) test-early experience. J Matern Fetal Neonatal Med. 2012; 25: 1856-9.

12. Dirección General de Información en Salud (DGIS). Base de datos de defunciones generales 1979-2007 [en línea]. Sistema Nacional de Información en Salud (SINAIS). México: Secretaría de Salud. Disponible en: http://www.sinais.salud.gob.mx (Consulta: 01 abril 2009)

13. Rosetalli M, Saba L. Prenatal diagnosis of β-thalassemias and hemoglobinopathies. Mediterr J Hematol Infect Dis. 2009; 1: e2009011.

14. Codori A, Slavney P, Rosenblantt A, Brandt J. Prevalence of major depression one year after predictive testing for Huntington disease. Genet Test. 2004; 8: 114-9.

15. Robins W. To know or not know: a review of behavior and suicidal in preclinical Huntington disease. Patient Educ Couns. 2007; 65: 279-87.

16. Takala T. The right to genetic ignorance confirmed. Bioethics. 1999; 13: 288-93.

17. Erez A, Plunkett K, Sutton V, McGuire A. The right to ignore genetic status of late onset genetic disease in the genomic era; prenatal testing for Huntington disease as a paradigm. Am J Med Genet A. 2010; 152A: 1774-80.

18. Alonso-Vilatela M, Ochoa-Morales A, García-de la Cadena C, Ruiz-López I, Martínez-Aranda C et al. Predictive and prenatal diagnosis of Huntington’s disease: attitudes of Mexican neurologists, psychiatrists, and psychologists. Archives of Medical Reserch. 1999; 30: 320-4.

19. Wilmoth G, de Alteriis M, Bussell D. Prevalence of psychological risks following legal abortion in the US: limits of the evidence. J Soc Iss. 1992; 48: 37-66.

20. Gissler M, Berg C, Bouvier-Colle M, Buekens P. Pregnancy-associated mortality after birth, spontaneous abortion or induced abortion in Finland, 1987-2000. Am J Obstet Gynecol. 2004; 190: 422-7.

21. Beauchamp T, Childress J. Principios de la ética biomédica. Barcelona: Masson, SA; 1999.

22. Wertz DC, Fletcher JC, Berg K. Guidelines on ethical issues in medical genetics and the provision of genetics services. Geneva: World Health Organization 1995, rev 1996 (Documents: WHO/HDP/GL/ETHI/95.1).

23. Goh AM, Chiu E, Yastrubetskaya O, Erwin C, Williams JK, Juhl AR et al. Perception, experience, and response to genetic discrimination in Huntington’s disease: the Australian results of the international respond HD study. Genet Test Mol Biomarkers. 2013; 17: 115-21.

24. Acosta-Sariego JR. La bioética de Potter a Potter. En: Acosta-Sariego JR, ed. Bioética para la sustentabilidad. La Habana: Publicaciones Acuario. Centro Félix Varela; 2002: p. 13-23.